Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

ERMA's flawed decision reveals inadequacies

Press release- GE Free NZ- 3 May 2001

ERMA's flawed decision reveals inadequacies in the system. Yesterday's High Court decision supports ethical and environmental concerns.

"Trials of this type puts public health and the reputation of our quality exports at risk. The use of New Zealand as a testing ground for this type of research is unconscionable. We have already been informed that any detrimental result from these trials will have to be paid for by the New Zealand public."

"We are not against medical research in containment but have been given no assurances that cross-species infections will not result from the testing of transgenic animals with human genes in the open environment. There is as yet no evidence that a cure for multiple sclerosis will result, the increasing incidence of MS may also be a result of aspartame poisoning from diet products according to a recent world symposium on aspartame. Many of today's illnesses have been caused by modern foods and chemicals."

So far ERMA have approved all GE trials in our environment, despite strong evidence of risks being presented in submissions against the various trials.

The public is not only expected to pay for this type of debatable research but may also be expected to pay for a cleanup should any problems eventuate. Should there be any resulting profits from this research, it will of course be hived off by Celentis.

UK company PPL have also been trialling transgenic animals, something they could not have done in the UK without intense public opposition.We feel that PPL's approval for sheep with human genes should be reassessed in light of this decision.

Background

Agresearch's trial of cows with human genes was eventually approved in July year after some controversy. In October, Agresearch formed a stand alone company Celentis, which after signing a major partnership agreement with CSL, Australia's largest investor in biopharmaceutical research, signed up for a similar venture with PPL Therapeutics to focus on the production of pharmaceutical and nutraceutical protein from the milk of transgenic cows. On April 11th this year an article in the UK Guardian stated that PPL have failed to raise funds on the stock market and may have to go 'cap in hand' to its development partner Bayer, facing a real struggle to pay for its new factory. "As one online investor stated 'without a manufacturing plant there can be no profits.' said Andrew Clark- The Guardian" PPL were given an approval to trial transgenic sheep under the old IAG Act- pre HSNO and now have an approval from ERMA granted in 1999 to breed a flock of 10,000 sheep with human genes.

In a media release this March, Agresearch posted a 41.5% profit rise boosted by a 71% increase in non-governmental commercial revenue and the acquisition of Sastek, a joint venture world leader in the supply of product traceability solutions and identification systems for the perishable food industry with allied companies in South Africa, Australia and the UK.

At present a joint proposal to Codex AlimentariusCommission (World Food Standards meeting in Ottawa until 4th May) by Australia and South Africa poses a threat against the only means consumers worldwide have of identifying non GE food by 'negative labelling'(GE/GM Free), and growing concerns about the health risks of meat have identified industrialised farming practices as perpetuating disease spread such as foot and mouth and BSE. The concerns of the human health risks of GE fed animals have been raised before the Royal Commission. The meat industry is considered a stakeholder by the Australian and New Zealand Food Authority (ANZFA) and having lobbied ANZFA to disallow labelling of meat (or other products produced from animals fed GE feeds) it is in all likelihood now lobbying Codex.

Further info- Susie Lees 03 546 7966 susie@tasman.net

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Voluntary Administration: Renaissance Brewing Up For Sale

Renaissance Brewing, the first local company to raise capital through equity crowdfunding, is up for sale after cash flow woes and product management issues led to the appointment of voluntary administrators. More>>

Elsewhere:

Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>

ALSO:

Media Mega Merger: Full Steam Ahead For Appeal

New Zealand's two largest news publishers have confirmed they are committed to pursuing their appeal against the Commerce Commission's rejection of the proposal to merge their operations. More>>

Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>

ALSO:

Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>